Physician profile
Craig E Keller
NPI 1831481365
$3,440.04
in general payments reported to CMS, 2019-2025
22 companies · $619 in 2025
The $619 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $42.04 · 2021: $340 · 2022: $643 · 2023: $848 · 2024: $774 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,354.00 | 2020-2025 | |
| Janssen Biotech, INC. | $399.15 | 2021-2024 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $283.58 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.51 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $209.08 | 2019-2024 | |
| Genzyme Corporation | $134.94 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $103.11 | 2022-2023 | Dupixent |
| Celgene Corporation | $90.48 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $87.67 | 2022-2023 | Rebyota |
| Qol Medical, LLC | $85.06 | 2022-2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $80.37 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $58.18 | 2023-2024 | Ocaliva |
| Gilead Sciences, INC. | $45.88 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $44.11 | 2024-2025 | Vowst |
| Madrigal Pharmaceuticals | $42.41 | 2025 | Rezdiffra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $38.79 | 2022 | |
| Allergan, INC. | $36.02 | 2019-2020 | |
| Ardelyx, INC. | $24.29 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $23.97 | 2023 | Injectafer |
| Ironwood Pharmaceuticals, INC | $18.16 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.52 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.